Pat Garcia-Gonzalez
Biographic Data
| ID | 9005404 |
|---|---|
| NAME | Pat Garcia-Gonzalez |
| GIVEN NAMES | Pat |
| FAMILY NAME | Garcia-Gonzalez |
| SIGNATURE | GARCIA-GONZALEZ P |
| ORCID | 0000-0002-4544-9253 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2009 |
| LATEST PUBLICATION YEAR | 2018 |
| H-INDEX | 0 |
A pharmacovigilance system for treatment access and medical donation programs
BACKGROUND: Cancer is a major burden of disease in low- and middle-income countries (LMICs) yet financial barriers limit access to life-saving oncology drugs. Medical donation and other drug access programs can help improve patient access to essential medicines, such as quality assured oncology drugs in LMICs. However, there are no published examples of the conduct of pharmacovigilance with donated medical products intended for use in LMICs where…
Benefits of global partnerships to facilitate access to medicines in developing countries
BACKGROUND: Access to medicines in developing countries continues to be a significant problem due to lack of insurance and lack of affordability. Chronic Myeloid Leukemia (CML), a rare disease, can be treated effectively, but the pharmaceutical treatment available (imatinib) is costly and unaffordable by most patients. GIPAP, is a programme set up between a manufacturer and an NGO to provide free treatment to eligible CML patients in 80 countries…
No prominent works on this page.
Benefits of global partnerships to facilitate access to medicines in developing countries
BACKGROUND: Access to medicines in developing countries continues to be a significant problem due to lack of insurance and lack of affordability. Chronic Myeloid Leukemia (CML), a rare disease, can be treated effectively, but the pharmaceutical treatment available (imatinib) is costly and unaffordable by most patients. GIPAP, is a programme set up between a manufacturer and an NGO to provide free treatment to eligible CML patients in 80 countries…
A pharmacovigilance system for treatment access and medical donation programs
BACKGROUND: Cancer is a major burden of disease in low- and middle-income countries (LMICs) yet financial barriers limit access to life-saving oncology drugs. Medical donation and other drug access programs can help improve patient access to essential medicines, such as quality assured oncology drugs in LMICs. However, there are no published examples of the conduct of pharmacovigilance with donated medical products intended for use in LMICs where…
Family medicine (2 works) · Medicine (2 works) · Pharmaceutical Economics and Policy (2 works) · Adverse effect (1 work) · Demography (1 work) · Developing country (1 work) · Disease (1 work) · Donation (1 work) · Economic growth (1 work) · Economics (1 work)